secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001437749-26-010105
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences awards CTO Darrin Uecker 100,000 RSUs for AFib product development
--------------------------------------------------------------------------------

- Restricted stock units cover 100,000 shares of common stock, par value $0.001.
- Grant vests in full on third anniversary of March 23, 2026 grant date.
- Award made under Amended and Restated 2017 Equity Incentive Plan.
- Compensation Committee granted for continued leadership in atrial fibrillation treatment product development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926010105/0001437749-26-010105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926010105/plse20260327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer